Leverage • Vir Biotechnology
VIR
Vir Biotechnology Inc., founded in 2016, is a clinical-stage biopharmaceutical company that develops innovative immunologic therapies to combat serious infectious diseases such as COVID-19 and hepatitis B. Operating within the Health Care sector, the company emphasizes leveraging advanced scientific research to meet significant unmet medical needs. Vir Biotechnology generates revenue primarily through strategic collaborations, licensing agreements, and milestone-based payments tied to its therapeutic candidates. Its business model is centered on partnering with global pharmaceutical companies and government agencies to bring novel treatments from development to commercialization. The company’s leading product candidate is VIR-7831 (sotrovimab), a monoclonal antibody that received emergency use authorization for COVID-19 treatment, forming a critical part of its portfolio. In addition, Vir is actively expanding its pipeline with candidates targeting hepatitis B and influenza, supported by collaborations with major pharma partners. Its integrated approach combines rigorous clinical development with advanced computational methods to enhance the safety and efficacy profiles of its treatments. Vir Biotechnology is led by CEO George Scangos, a veteran in the biotechnology industry with extensive experience in steering innovative drug development initiatives. Alongside him, a team of seasoned executives in research and commercialization drives the company’s strategic clinical operations and partnerships. Vir holds a competitive stature among biotech firms focused on infectious diseases, with its innovative product pipeline contributing to a market capitalization exceeding $3 billion. Strategic alliances and early successes, especially in COVID-19 therapeutics, have positioned the company as an influential player in a niche market with significant growth potential. Looking forward, Vir Biotechnology plans to advance multiple candidates through clinical trials while exploring new indications and expanding its portfolio to address broader infectious disease challenges. The company is focused on achieving key regulatory milestones, deepening its strategic partnerships, and leveraging its innovative platform to drive long-term revenue growth.
0,8
N.D./EBITDA
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
0%
Debt/Equity
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
5,5
Current Ratio
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
5
Quick Ratio
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
—
Interest Coverage
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!